// App-Quantinova.ai

: AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.

Researchers

Presenter

  • Paraskevi Giannakakou

Principal Investigators

  • Giuseppe Galletti

  • Daniel Worroll

  • John Stewart

  • Atef Zaher

  • Ted P. Szatrowski

  • Wei Zhou

  • Karla V. Ballman

  • Marie Vanhuyse

  • Ada Gjyrezi

  • Shinsuke Tasaki

  • Yang Bai

  • Luigi Portella

  • Brian J. Kirby

  • Guru Sonpavde

  • Mario A. Eisenberger

  • David M. Nanus

  • Fred Saad

  • Scott T. Tagawa

Medical Centers

  • Weill Cornell Medicine/Meyer Cancer Center, New York, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Sanofi, Laval, QC, Canada

  • Sanofi, Bridgewater, NJ

  • Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, NY

  • Medical Oncology, Montreal General Hospital, Montreal, QC, Canada

  • Cornell University, Ithaca, NY

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

  • taxane

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT01718353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved